Edition:
United States

Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

28.53USD
3:59pm EST
Change (% chg)

$-0.60 (-2.06%)
Prev Close
$29.13
Open
$29.24
Day's High
$29.50
Day's Low
$28.48
Volume
43,774
Avg. Vol
63,205
52-wk High
$33.26
52-wk Low
$14.00

Chart for

About

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the... (more)

Overall

Beta: --
Market Cap(Mil.): $869.69
Shares Outstanding(Mil.): 29.86
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Audentes Therapeutics Q3 ‍loss per share $ 0.88​

* Audentes Therapeutics reports third quarter 2017 financial results and provides corporate update

Nov 14 2017

BRIEF-Audentes Therapeutics to release Q3 financial results Nov. 14

* Audentes Therapeutics to release third quarter 2017 financial results and provide corporate update on Tuesday, November 14, 2017 Source text for Eikon: Further company coverage:

Nov 07 2017

BRIEF-Audentes Therapeutics gets fast track designation for its muscle disorder drug

* Audentes Therapeutics announces rare pediatric disease and fast track designations for AT132 for the treatment of x-linked myotubular myopathy

Sep 27 2017

BRIEF-Audentes Therapeutics commences dosing of first patient in phase 1/2 trial of AT132 for the treatment of x-linked myotubular myopathy

* Audentes Therapeutics announces dosing of first patient in ASPIRO, a phase 1/2 clinical trial of AT132 for the treatment of X-linked myotubular myopathy

Sep 21 2017

BRIEF-Audentes Therapeutics files for mixed shelf offering of up to $250 mln‍​

* Audentes Therapeutics Inc files for mixed shelf offering of up to $250 million - sec filing‍​ Source text: (http://bit.ly/2fqe6ME) Further company coverage:

Aug 08 2017

BRIEF-Audentes Therapeutics appoints Fulvio Mavilio to vice president scientific affairs, Europe

* Audentes Therapeutics announces appointment of Fulvio Mavilio, Ph.D. To vice president scientific affairs, Europe Source text for Eikon: Further company coverage:

Jul 18 2017

Earnings vs. Estimates